Acute Lymphoblastic LeukemiaGMALLregistryNCT02872987
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
An observational study of Acute Lymphoblastic Leukemia and Leukemia, run by Goethe University at 147 sites in 2 countries.
Trial summary
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Lymphoblastic Leukemia, Leukemia, Non-Hodgkin's Lymphoma
- How many people
- 10,000 participants
- Where
- 147 sitesin 2 countries
- Study dates
- Feb 2009to Dec 2035
- How long will I take part?
- 15 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Acute Lymphoblastic Leukemia or seleted NHL
Who may be able to join
- Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols
- Other Types of Leukemia (NK Cell Lymphoma/Leukemia, Biphenotypic Acute Leukemia) if treated according to ALL protocols
- Non-Hodgkin's Lymphoma of Following Subtypes: Burkitt Lymphoma, B Cell Lymphoma, B- or T-lineage Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Other NHL) if treated according to B-ALL protocols
- Age minimum 18 yrs
Who cannot join
None listed.
Trial locations and contacts
147 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
GMALL Study center contact
147 sites in 2 countries
Germany142 sites, 142 recruiting
- Recruiting
Universitätsklinikum Aachen
Aachen
- Recruiting
Klinikum Altenburger Land
Altenburg
- Recruiting
Kreiskliniken Altötting
Altötting
- Recruiting
Klinikum Aschaffenburg
Aschaffenburg
- Recruiting
Klinikum Augsburg
Augsburg
- Recruiting
Helios Klinikum Bad Saarow
Bad Saarow
- Recruiting
Sozialstiftung Bamberg
Bamberg
- Recruiting
Klinikum Bayreuth
Bayreuth
- Recruiting
Charité Universitätsmedizin Berlin
Berlin
- Recruiting
Evangelisches Waldkrankenhaus Spandau
Berlin
- Recruiting
Helios Klinikum Berlin-Buch
Berlin
- Recruiting
Vivantes Klinikum Neukölln
Berlin
- Recruiting
Vivantes-Klinikum am Urban
Berlin
- Recruiting
Evangelisches Krankenhaus Bielefeld
Bielefeld
- Recruiting
Klinikum Bielefeld
Bielefeld
- Recruiting
Augsuta Krankenanstalt Bochum
Bochum
- Recruiting
Katholisches Klinikum Bochum
Bochum
- Recruiting
Universitätsklinikum Knappschaftskrankenhaus Bochum
Bochum
- Recruiting
Johanniter-Krankenhaus Bonn
Bonn
- Recruiting
Universitätsklinikum Bonn
Bonn
- Recruiting
Städtisches Klinikum Braunschweig
Braunschweig
- Recruiting
Evangelische Diakonissenanstalt Bremen
Bremen
- Recruiting
Klinikum Bremen-Mitte gGmbH
Bremen
- Recruiting
Klinikum Chemnitz gGmbH
Chemnitz
- Recruiting
Universitätsklinikum Köln
Cologne
- Recruiting
Carl-Thiem-Klinikum Cottbus
Cottbus
- Recruiting
Klinikum Darmstadt
Darmstadt
- Recruiting
Städtisches Krankenhaus Dessau
Dessau
- Recruiting
Klinikum Dortmund
Dortmund
- Recruiting
St. Johannes-Hospital Dortmund
Dortmund
- Recruiting
Klinikum Carl-Gustav-Carus
Dresden
- Recruiting
Städtisches Klinikum Dresden
Dresden
- Recruiting
Helios Klinikum Duisburg
Duisburg
- Recruiting
Johanniter-Krankenhaus Duisburg
Duisburg
- Recruiting
Krankenhaus Düren
Düren
- Recruiting
Marien-Hospital Düsseldorf
Düsseldorf
- Recruiting
Universitätsklinikum Düsseldorf
Düsseldorf
- Recruiting
Helios Klinikum Erfurt
Erfurt
- Recruiting
Universitätsklinikum Erlangen
Erlangen
- Recruiting
St.-Antonius-Hospital Eschweiler
Eschweiler
- Recruiting
Evang. Krankenhaus Essen-Werden
Essen
- Recruiting
Universitätsklinikum Essen
Essen
- Recruiting
Malteser Krankenhaus Flensburg
Flensburg
- Recruiting
Klinikum Frankfurt-Oder
Frankfurt
- Recruiting
Städt. Klinikum Frankfurt-Höchst
Frankfurt
- Recruiting
University Hospital of Frankfurt (Main)
Frankfurt am Main, Hesse, 60590
GMALL Study Center, +496963016366, gmall@em.uni-frankfurt.de
Nicola Gökbuget, Dr. med.
- Recruiting
Universitätsklinikum Freiburg
Freiburg im Breisgau
- Recruiting
Klinikum Fulda
Fulda
- Recruiting
Niels-Stensen-Kliniken Georgsmarienhütte
Georgsmarienhütte
- Recruiting
Klinik der Justus-Liebig-Universität Gießen
Giessen
- Recruiting
Wilhelm-Anton-Hospital Goch
Goch
- Recruiting
Universitätsklinikum Göttingen
Göttingen
- Recruiting
Universitätsklinikum Ernst-Moritz-Arndt-Universität
Greifswald
- Recruiting
Städtisches Krankenhaus Gütersloh
Gütersloh
- Recruiting
Katholisches Krankenhaus Hagen gGmbH
Hagen
- Recruiting
Krankenhaus St. Elisabeth und St. Barbara Halle/Saale
Halle
- Recruiting
Martin-Luther-Universität Halle-Wittenberg
Halle
- Recruiting
Asklepios Klinik Altona Hamburg
Hamburg
- Recruiting
Asklepios Klinik St. Georg Hamburg
Hamburg
- Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg
- Recruiting
Evangelisches Krankenhaus Hamm gGmbH
Hamm
- Recruiting
St. Barbara-Klinik Hamm
Hamm
- Recruiting
Klinikum Siloah Hannover
Hanover
- Recruiting
Medizinische Hochschule Hannover
Hanover
- Recruiting
Universitätsklinikum Heidelberg
Heidelberg
- Recruiting
SLK Kliniken Heilbronn
Heilbronn
- Recruiting
Marienhospital Herne
Herne
- Recruiting
St. Bernward Krankenhaus Hildesheim
Hildesheim
- Recruiting
Universitätsklinikum des Saarlandes
Homburg/Saar
- Recruiting
Klinikum Idar-Oberstein
Idar-Oberstein
- Recruiting
Universitätsklinikum Jena
Jena
- Recruiting
St. Vincentius-Kliniken Karlsruhe
Karlsruhe
- Recruiting
Städt. Klinikum Karlsruhe
Karlsruhe
- Recruiting
Klinikum Kassel GmbH
Kassel
- Recruiting
Städtisches Krankenhaus Kiel
Kiel
- Recruiting
Universitätsklinikum Schleswig-Holstein
Kiel
- Recruiting
Gemeinschaftsklinikum Mittelrhein Koblenz
Koblenz
- Recruiting
Helios Klinikum Krefeld
Krefeld
- Recruiting
Klinikum Kulmbach
Kulmbach
- Recruiting
Klinikum Landshut
Landshut
- Recruiting
Universitätsklinikum Leipzig
Leipzig
- Recruiting
Klinikum Lippe-Lemgo
Lippe
- Recruiting
Sana Kliniken Lübeck
Lübeck
- Recruiting
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck
- Recruiting
Märkische Kliniken Lüdenscheid
Lüdenscheid
- Recruiting
Klinikum der Stadt Ludwigshafen
Ludwigshafen
- Recruiting
Universitätsklinikum Magdeburg
Magdeburg
- Recruiting
Universitätsklinikum Mainz
Mainz
- Recruiting
Klinikum Mannheim
Mannheim
- Recruiting
Universitätsklinikum Marburg
Marburg
- Recruiting
Klinikum Hochsauerland Meschede
Meschede
- Recruiting
Johannes Wesling Klinikum Minden
Minden
- Recruiting
Kliniken Maria Hilf Mönchengladbach
Mönchengladbach
- Recruiting
Klinikum München-Bogenhausen
München
- Recruiting
Klinikum Rechts der Isar der TU München
München
- Recruiting
Rotkreuzklinikum München
München
- Recruiting
Städtisches Krankenhaus München-Neuperlach
München
- Recruiting
Universitätsklinikum München-Großhadern
München
- Recruiting
Universitätsklinikum Münster
Münster
- Recruiting
Stauferklinikum Mutlangen
Mutlangen
- Recruiting
Dietrich-Bonhoeffer-Klinikum Neubrandenburg
Neubrandenburg
- Recruiting
Südharz Klinikum Nordhausen
Nordhausen
- Recruiting
Klinikum Nürnberg Nord
Nuremberg
- Recruiting
Ortenau Klinikum Offenburg
Offenburg
- Recruiting
Klinikum Oldenburg
Oldenburg
- Recruiting
Pius-Hospital Oldenburg
Oldenburg
- Recruiting
Klinikum Osnabrück
Osnabrück
- Recruiting
Brüderkrankenhaus St. Josef Paderborn
Paderborn
- Recruiting
Klinikum Passau
Passau
- Recruiting
Klinikum Ernst von Bergmann
Potsdam
- Recruiting
Kliniken Vest Recklinghausen
Recklinghausen
- Recruiting
Krankenhaus Barmherzige Brüder Regensburg
Regensburg
- Recruiting
Universitätsklinikum Regensburg
Regensburg
- Recruiting
Kreiskliniken Reutlingen
Reutlingen
- Recruiting
Elblandklinikum Riesa
Riesa
- Recruiting
Klinikum Südstadt Rostock
Rostock
- Recruiting
Universitätsklinikum Rostock
Rostock
- Recruiting
Diakoniekrankenhaus Rotenburg
Rotenburg (Wümme)
- Recruiting
Marienhaus Klinikum Saarlouis
Saarlouis
- Recruiting
Nordwest-Krankenhaus Sanderbusch
Sande
- Recruiting
Diakonie-Krankenhaus
Schwäbisch Hall
- Recruiting
Helios Klinikum Schwerin
Schwerin
- Recruiting
Ev. Jung-Stilling Krankenhaus Siegen
Siegen
- Recruiting
St. Marienkrankenhaus Siegen
Siegen
- Recruiting
Klinikum Südwest Sindelfingen
Sindelfingen
- Recruiting
Diakonissen-Stiftungs-Krankenhaus Speyer
Speyer
- Recruiting
Diakonie-Klinikum Stuttgart
Stuttgart
- Recruiting
Klinikum Stuttgart Katharinenhospital
Stuttgart
- Recruiting
Marienhospital Stuttgart
Stuttgart
- Recruiting
Robert-Bosch-Krankenhaus
Stuttgart
- Recruiting
Klinikum Traunstein
Traunstein
- Recruiting
Krankenhaus der Barmherzigen Brüder
Trier
- Recruiting
Mutterhaus der Borromäerinnen Trier
Trier
- Recruiting
Universitätsklinikum Tübingen
Tübingen
- Recruiting
Medizinische Universitätsklinikum Ulm
Ulm
- Recruiting
Klinikum Schwarzwald-Baar Villingen
Villingen-Schwenningen
- Recruiting
Helios Dr. Horst Schmidt Kliniken Wiesbaden
Wiesbaden
- Recruiting
Rems-Murr-Kliniken Winnenden
Winnenden
- Recruiting
Klinikum der Stadt Wolfsburg
Wolfsburg
- Recruiting
Helios Klinikum Wuppertal
Wuppertal
- Recruiting
Universitätsklinikum Würzburg
Würzburg
- Recruiting
Heinrich-Braun-Klinikum Zwickau
Zwickau
Austria5 sites, 5 recruiting
- Recruiting
Universitätsklinikum Graz
Graz
- Recruiting
LKH-Hochsteiermark Leoben
Leoben
- Recruiting
Ordensklinikum Linz Elisabethinen
Linz
- Recruiting
Universitätsklinikum St. Pölten
Sankt Pölten
- Recruiting
Hanusch-Krankenhaus Wien
Vienna
About this study
Official title: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult ALL Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
- Medical subject headings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| B-ALL/NHL | Not described | |
| ALL/ Lymphoblastic Lymphoma (LBL) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: up to 10 years
Secondary outcomes (13)
Event free survival
Measured: up to 10 years
Hematologic remission rate
Measured: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Molecular remission rate
Measured: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Positron Emission Tomography (PET) based remission evaluation
Measured: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Remission duration
Measured: up to 10 years
Relapse rate
Measured: up to 10 years
Disease free survival
Measured: up to 10 years
Early mortality
Measured: during induction therapy with a duration of approximately 6 - 8 weeks
Mortality in Clinical Remission (CR)
Measured: up to 10 years
Comorbidities
Measured: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Quality of life assessed by Quality of Life Questionnaire (QLQ-C30)
Measured: after treatment which is approximately 2.5 years from diagnosis
Eastern Cooperative Oncology Group (ECOG) status
Measured: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Toxicities assessed by CTCAE v4.03
Measured: during treatment with an approximate duration of 2.5 years from diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2016 (estimated)
- Study startFeb 2009
- Primary completionDec 2030 (estimated)
- Study completionDec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Lymphoblastic LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 15 Years
Sponsor and investigators
- Lead sponsor
- Goethe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nicola Goekbuget, Goethe University
- Investigators
- Nicola Gökbuget, Dr. med., Principal investigator, University Hospital of Frankfurt (Main)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02872987
- Sponsor's protocol ID
- GMALL_Registry
- Acronym
- GMALLregistry
- Status last verified
- Nov 2025
- First submitted
- 4 Aug 2016
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult ALL Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
- ClinicalTrials.gov ID
- NCT02872987
- Acronym / sponsor ID
- GMALLregistry / GMALL_Registry
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Goethe UniversityUniversity, hospital or other
- Study start
- Feb 2009
- Primary completion
- Dec 2030 (estimated)
- Study completion
- Dec 2035 (estimated)
- First posted
- 19 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 15 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| B-ALL/NHL | – | – |
| ALL/ Lymphoblastic Lymphoma (LBL) | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Acute Lymphoblastic Leukemia or seleted NHL
Key inclusion criteria (4 listed)
- Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols
- Other Types of Leukemia (NK Cell Lymphoma/Leukemia, Biphenotypic Acute Leukemia) if treated according to ALL protocols
- Non-Hodgkin's Lymphoma of Following Subtypes: Burkitt Lymphoma, B Cell Lymphoma, B- or T-lineage Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Other NHL) if treated according to B-ALL protocols
- Age minimum 18 yrs
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall survival
Time frame: up to 10 years
13 secondary outcomes
Event free survival
Time frame: up to 10 years
Hematologic remission rate
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Molecular remission rate
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Positron Emission Tomography (PET) based remission evaluation
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Remission duration
Time frame: up to 10 years
Relapse rate
Time frame: up to 10 years
Disease free survival
Time frame: up to 10 years
Early mortality
Time frame: during induction therapy with a duration of approximately 6 - 8 weeks
Mortality in Clinical Remission (CR)
Time frame: up to 10 years
Comorbidities
Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Quality of life assessed by Quality of Life Questionnaire (QLQ-C30)
Time frame: after treatment which is approximately 2.5 years from diagnosis
Eastern Cooperative Oncology Group (ECOG) status
Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Toxicities assessed by CTCAE v4.03
Time frame: during treatment with an approximate duration of 2.5 years from diagnosis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Lymphoblastic Leukemia
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
GMALL Study center contact
Nicola Gökbuget, Dr. med. principal investigator
University Hospital of Frankfurt (Main)
147 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Lymphoblastic Leukemia and Leukemia, run by Goethe University at 147 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 147 sites in Germany, Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicola Gökbuget, Dr. med. (+496963016365, goekbuget@em.uni-frankfurt.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.